Supernus receives $2M milestone payment for launch of Orenitram Supernus Pharmaceuticals (SUPN) announced that United Therapeutics Corporation (UTHR) has paid Supernus a $2M milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
News For SUPN;UTHR From The Last 14 Days
Check below for free stories on SUPN;UTHR the last two weeks.